XenoPort, Inc. (Nasdaq: XNPT) announced top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE